| Identification | Back Directory | [Name]
Research Grade Casirivimab (DVV00304) | [CAS]
2415933-42-3 | [Synonyms]
Casirivimab Research Grade Casirivimab Research Grade Casirivimab (DVV00304) |
| Hazard Information | Back Directory | [Uses]
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms[1][2]. | [in vivo]
Casirivimab (400 μg (Casirivimab and imdevimab), intraperitoneal injection, single dose) has shown positive results against the δ variant when used in combination with imdevimab, but its antiviral effectiveness appears to be weakened when dealing with the Omicron variant[2]. | Animal Model: | K18-hACE2 mice vaccinated with the SARS-CoV-2 δ or Omicron variant[2] | | Dosage: | 400μg; single dose | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Decreased amount of subgenomic E RNA (sgE RNA), which reduced the viral load and improved lung pathology in δ. Weakened antiviral effectiveness in the body against Omicron. |
| [References]
[1] Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15. PMID:33226742 [2] Lee Tatham, et al. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Microbiol Spectr. 2024 Aug 6;12(8):e0391623. DOI:10.1128/spectrum.03916-23 |
|
| Company Name: |
Biolab Reagents
|
| Telephone: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|